Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 4Lymphoid 1CNS 1

Conditions

Lymphoma 341Precursor Cell Lymphoblastic Leukemia-Lymphoma 264Leukemia, Lymphocytic, Chronic, B-Cell 249Lymphoma, Non-Hodgkin 227Lymphoma, Large B-Cell, Diffuse 208Lymphoma, Follicular 201Burkitt Lymphoma 183Lymphoma, Mantle-Cell 166Leukemia 148Lymphoma, B-Cell, Marginal Zone 145Hodgkin Disease 141Lymphoma, Large-Cell, Immunoblastic 124Lymphoma, T-Cell, Cutaneous 108Leukemia, Myeloid, Acute 106Multiple Myeloma 97Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 96Lymphoma, Large-Cell, Anaplastic 96Mycosis Fungoides 90Sezary Syndrome 87Waldenstrom Macroglobulinemia 84Immunoblastic Lymphadenopathy 73Neoplasms 60Myelodysplastic Syndromes 59Blast Crisis 57Intraocular Lymphoma 49Hematologic Neoplasms 46Congenital Abnormalities 45Myeloproliferative Disorders 44Dendritic Cell Sarcoma, Interdigitating 44Leukemia, Myelomonocytic, Chronic 42

Interventions

BAY 1895344 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Rhabdomyosarcoma, Alveolar × Lymphoid × Clear all
NCT05071209 2026-01-23

Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
31 enrolled 14 charts
LymphoidSarcoma

Lymphoma, Sarcoma, Ewing, Rhabdomyosarcoma, Alveolar

Data powered by HemOnc (CC BY 4.0) Colophon âš¡